Click HERE to register for our upcoming FREE Q&A webinar on ketamine regulations and the future of therapeutic psychedelic medicines!
In the next few years, the FDA will likely approve drug formulations containing psilocybin and MDMA. While there are still many unknowns concerning how psilocybin and MDMA-based drug therapies will be regulated, we believe that many of the same trends we have seen over the last few years in ketamine therapy will apply to these new drug therapies.
To that end, Harris Bricken attorneys will offer a free webinar on Tuesday, April 11 @ 10:00am PT in which we will address the current regulatory landscape for ketamine, some potential bigger regulatory changes on the horizon, as well as some of the key issues for future FDA-approved psychedelic drug therapies. The panel will be moderated by Hilary Bricken (Los Angeles), with panelists Griffen Thorne (Los Angeles) and Ethan Minkin (Phoenix). Panelists will take questions throughout the webinar.
Register HERE today! And feel free to submit any panelist questions you have when you register.
Until then, more information can be found on our psychedelics page.
